1. Scrip

Gene Therapies: Waiting To Emerge From The Bottle

 
• By Natasha Boliter

Slowly but surely, gene therapy projects are winning back confidence from the industry and as investment increases, so increase the reports on progress in this area; from sensational claims of restoring sight, to slightly more spurious claims of reversing the aging process.

Magic lamp

Gene therapy has been heralded as the ‘Next Big Thing’, not once, but twice. Since its dramatic fall from grace following extreme clinical trial mortalities at the end of the 1990s, investment in the area was widely reported as drying up, but as Figure 1 shows, gene therapy research never really went away.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.